共 129 条
[1]
Schlagenhauf P(2011)Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data MalarJ 10 292-121
[2]
Adamcova M(2007)UK malaria treatment guidelines J Infection 54 111-812
[3]
Regep L(2006)Malaria protection for short-term travelers Internist 47 810-512
[4]
Schaerer MT(2004)Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine Br J Clin Pharmacol 57 506-641
[5]
Bansod S(2003)Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study BMJ 327 1078-165
[6]
Rhein HG(2004)The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study Ann Trop Med Parasitol 98 639-1528
[7]
Lalloo DG(1999)Improved validated assay for the determination of mefloquine and its carboxy metabolite in plasma, serum and whole blood using solid-phase extraction and high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 727 159-65
[8]
Shingadia D(2009)Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Malar J 8 58-1576
[9]
Pasvol G(2006) malaria Pharmacotherapy 26 1526-132
[10]
Chiodini PL(2003) malaria associated with mefloquine failure in Gambia Acta Trop 86 63-261